Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (176 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: in subjectsuncontrolledrelapsedbmsrefractory
  Phrases that lowered it: pharmacokineticsmultipleevaluate theto evaluatedisorder
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports with a death: 29.7% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 115 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past termination rate: 7.9% (raises risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 190 (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Allocation: non randomized (lowers risk) · Design
• Drug's FAERS reports before start: 20941 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT01359657 · started 2011 · scored riskier than 52% of active trials completed
• A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy NCT01794507 · started 2012 · scored riskier than 34% of active trials completed
• Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma NCT02462525 · started 2015 · scored riskier than 45% of active trials terminated
• BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma NCT01638936 · started 2012 · scored riskier than 79% of active trials completed
• Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma NCT05289492 · started 2022 · scored riskier than 19% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.